Esperion Therapeutics, Inc.
Develops and commercializes oral medicines to reduce cardiovascular risk.
ESPR | US
Overview
Corporate Details
- ISIN(s):
- US29664W1053
- LEI:
- Country:
- United States of America
- Address:
- 3891 RANCHERO DRIVE, SUITE 150, 48108 ANN ARBOR
- Website:
- https://www.esperion.com/
- Sector:
- Manufacturing
Description
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines to reduce cardiovascular risk. The company specializes in once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its portfolio is centered around adenosine triphosphate-citrate lyase (ACLY) inhibitors, a unique mechanism of action for which it brought the first treatment to market. Key products include NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), which are approved in the U.S. and Europe. Esperion collaborates with commercial partners to facilitate global access to its medicines while its scientific team investigates new therapeutic opportunities through its pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Esperion Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Esperion Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Esperion Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
